Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia

15 Jan 2006

Abstract excerpt

It has been established in preclinical models of multiple myeloma and acute myeloid leukemia (AML) that the bone marrow microenvironment provides protection from chemotherapy- and death receptor-mediated apoptosis. This form of resistance, termed de novo drug resistance, occurs independent of chronic exposure to cancer-related therapies and likely promotes the development of multidrug resistance. Consequently, it...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16428505
DOI: 10.1158/1078-0432.ccr-05-1792

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid LeukemiaPMID 16428505Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

Environmental-mediated drug resistance: a target for multiple myeloma therapySemantic proximity Read ↗

Overcoming bortezomib resistance in multiple myelomaSemantic proximity Read ↗

Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironmentSemantic proximity Read ↗

Evidence for Cell Adhesion-Mediated Drug Resistance of Multiple Myeloma Cells in VivoSemantic proximity Read ↗

NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.Semantic proximity Read ↗

Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.Semantic proximity Read ↗

Cell adhesion down-regulates the expression of vacuolar protein sorting 4B (VPS4B) and contributes to drug resistance in multiple myeloma cells.Semantic proximity Read ↗

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma ModelSemantic proximity Read ↗

Resistance to proteasome inhibitors and other targeted therapies in myeloma.Semantic proximity Read ↗

Cadherins, Selectins, and Integrins in CAM-DR in LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.